Related Experiment Videos
PSA screening: a public health dilemma
M T Mandelson1, E H Wagner, R S Thompson
1Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA.
Annual Review of Public Health
|January 1, 1995
Summary
Prostate cancer screening using prostate-specific antigen (PSA) is controversial due to conflicting guidelines and lack of definitive mortality reduction data. This review examines prostate cancer epidemiology, PSA test accuracy, and treatment efficacy to clarify screening benefits.
Area of Science:
- Urology
- Oncology
- Public Health
Background:
- Prostate cancer screening with serum prostate-specific antigen (PSA) is a highly debated healthcare practice.
- Conflicting guidelines from professional and policy organizations highlight the controversy surrounding PSA screening.
- Prostate cancer exhibits a significant disparity between asymptomatic prevalent cancer and clinically diagnosed disease, with an uncertain natural history.
Purpose of the Study:
- To review the epidemiology and natural history of prostate cancer.
- To evaluate the diagnostic capabilities and operational characteristics of PSA as a screening test.
- To assess the efficacy of treatments for early-stage prostate cancer.
Main Methods:
- Literature review of prostate cancer epidemiology and natural history.
- Analysis of studies on PSA test performance for early cancer detection.
- Examination of data regarding the effectiveness of early prostate cancer treatments.
Main Results:
- PSA testing can detect early-stage prostate cancer.
- Definitive data demonstrating that PSA screening reduces prostate cancer mortality are currently unavailable.
- Disagreements in screening recommendations stem from differing views on acceptable screening benefits and required evidence levels.
Conclusions:
- The controversy surrounding PSA screening for prostate cancer is fueled by the lack of conclusive evidence for mortality reduction.
- Understanding prostate cancer's natural history and the performance of PSA testing is crucial for informed screening decisions.
- Further research is needed to establish clear guidelines for PSA screening based on robust evidence of benefit.